FACTS & FIGURES
New Clinical studies
Active Clinical studies
In 2025, the EMA recommended for approval 8 (out of 26) new active drugs based on clinical trials in which VHIR played a pivotal role.
Active Clinical studies
Pediatric (21%)
ATMP (1/3 of EMA & FDA approved CAR-T (not O-H)
Rare Diseases (22%)
Per disease
Patient inclusion
Total new patients
Pediatrics
ATMP
Definitions & methodology
The data are at VHIR level, not at Campus level (not including data from VHIO/Adult Oncology and Hematology Services).
The data includes commercial and academic studies that are registered in the database.
New: studies with signed contract+AEMPS+CEIm.
Active: active+new+closed studies in the year.
